More on LABT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings

Upcoming Events

- Earnings (12/2/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(NQ:LABT)
Delayed: 1.64 -0.19 (10.38%)
Prev. Close $1.83  
Open$1.85 
52 Wk High$ 
52 Wk Low$ 
Day High$1.85 
Day Low$1.63 
P/E N/A  
EPS$ 
Volume143,651 

Friends, Peers and Foes (?): ASBP, ATYR, COCH, CTSO, IMNN (more...)

Sep 25, 2026 06:03 AM Form EFFECT Lakewood-Amedex Biothera
Sep 24, 2026 08:03 AM Lakewood-Amedex doses first patient in diabetic foot ulcer trial
Sep 24, 2026 08:02 AM Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
Sep 21, 2026 08:03 AM Lakewood-Amedex outlines Nu-3 clinical progress after Nasdaq listing
Sep 21, 2026 08:02 AM Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
Sep 18, 2026 05:31 PM Form S-1 Lakewood-Amedex Biothera
Sep 18, 2026 04:03 PM Lakewood-Amedex gets IRB approval for diabetic foot ulcer trial
Sep 18, 2026 08:14 AM Lakewood-Amedex gets IRB approval for diabetic foot ulcer trial
Sep 18, 2026 08:14 AM Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers
Aug 17, 2026 04:45 PM Form 424B3 Lakewood-Amedex Biothera
View All Articles

Entities mentioned with LABT

View All Entities